Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;173(1):37-40.
doi: 10.1007/s10517-022-05488-1. Epub 2022 May 27.

Low-Molecular-Weight Perorally Active Nerve Growth Factor Mimetic Reduces Manifestations of Diabetic Neuropathy in Wistar Rats

S V Ivanov  1 , R U Ostrovskaya  2 , A S Khlybova  2 , T A Gudasheva  2
Affiliations

Low-Molecular-Weight Perorally Active Nerve Growth Factor Mimetic Reduces Manifestations of Diabetic Neuropathy in Wistar Rats

S V Ivanov et al. Bull Exp Biol Med. 2022 May.

Abstract

A low-molecular-weight nerve growth factor mimetic, compound GK-2 (bis-(N-monosuccinyl- L-glutamyl-L-lysine)hexamethylenediamide) that previously demonstrated antidiabetic activity in rats with streptozotocin-induced type 2 diabetes mellitus was studied on the model of diabetic neuropathy. It was found that in 8 weeks after diabetes mellitus development, untreated diabetic rats demonstrated impaired tactile sensitivity in von Frey test, while GK-2 therapy (7.5 mg/kg orally for 28 days) restored this parameter. The decrease of tactile sensitivity in diabetic neuropathy closely correlated with the severity of hyperglycemia (r=0.76). Our findings are consistent with the concept on the role of glucose toxicity and nerve growth factor deficiency in the pathogenesis of diabetic neuropathy and attest to feasibility of further studies of nerve growth factor mimetic GK-2 as a potential treatment for diabetes and diabetic neuropathy.

Keywords: GK-2; NGF; diabetes; diabetic neuropathy; neurotrophins.

PubMed Disclaimer

References

    1. Seredenin SB, Gudasheva TA. Patent RU No. 2410392. Dipeptide mimetics of NGF and BDNF neurotrophins. Bull. No. 24. Published August 27, 2010.
    1. Antipova TA, Gudasheva TA, Seredenin SB. In vitro study of neuroprotective properties of GK-2, a new original nerve growth factor mimetic. Bull. Exp. Biol. Med. 2011;150(5):607-609. https://doi.org/10.1007/s10517-011-1202-6 - DOI - PubMed
    1. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods. 1994;53(1):55-63. https://doi.org/10.1016/0165-0270(94)90144-9 - DOI - PubMed
    1. Dey I, Midha N, Singh G, Forsyth A, Walsh SK, Singh B, Kumar R, Toth C, Midha R. Diabetic Schwann cells suffer from nerve growth factor and neurotrophin-3 underproduction and poor associability with axons. Glia. 2013;61(12):1990-1999. https://doi.org/10.1002/glia.22570 - DOI - PubMed
    1. Gudasheva TA, Antipova TA, Seredenin SB. Novel lowmolecular-weight mimetics of the nerve growth factor. Dokl. Biochem. Biophys. 2010;434:262-265. https://doi.org/10.1134/S160767291005011X - DOI - PubMed

MeSH terms

LinkOut - more resources